Tuberous Sclerosis Complex

Afinitor Disperz Approved to Treat TSC-Associated Partial-Onset Seizures

Afinitor Disperz Approved to Treat TSC-Associated Partial-Onset Seizures

By

The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.

Vigabatrin Beneficial for Focal Seizures in Tuberous Sclerosis Complex

Vigabatrin Beneficial for Focal Seizures in Tuberous Sclerosis Complex

By

Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.

Factors Predictive of Everolimus Efficacy in Tuberous Sclerosis Complex

Factors Predictive of Everolimus Efficacy in Tuberous Sclerosis Complex

By

Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.

Everolimus Safe, Effective for Reduction of Seizures in Tuberous Sclerosis Complex

Everolimus Safe, Effective for Reduction of Seizures in Tuberous Sclerosis Complex

By

The EXIST-3 trial is the first phase 3 study to evaluate the use of EVE for the adjunctive treatment of seizures in TSC.

Everolimus Effective in Reducing Seizures in Tuberous Sclerosis Complex

Everolimus Effective in Reducing Seizures in Tuberous Sclerosis Complex

By

The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.

Sign Up for Free e-newsletters



CME Focus